CVAL.F Stock Overview
Engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Covalon Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.88 |
| 52 Week High | CA$3.08 |
| 52 Week Low | CA$0.73 |
| Beta | 0.62 |
| 11 Month Change | 27.03% |
| 3 Month Change | 42.57% |
| 1 Year Change | n/a |
| 33 Year Change | 56.52% |
| 5 Year Change | 127.67% |
| Change since IPO | 376.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| CVAL.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.2% | -10.5% | -2.1% |
| 1Y | n/a | 12.7% | 29.7% |
Return vs Industry: Insufficient data to determine how CVAL.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CVAL.F performed against the US Market.
Price Volatility
| CVAL.F volatility | |
|---|---|
| CVAL.F Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CVAL.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CVAL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Brent Ashton | www.covalon.com |
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device.
Covalon Technologies Ltd. Fundamentals Summary
| CVAL.F fundamental statistics | |
|---|---|
| Market cap | US$78.76m |
| Earnings (TTM) | -US$584.42k |
| Revenue (TTM) | US$20.72m |
3.8x
P/S Ratio-135.4x
P/E RatioIs CVAL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVAL.F income statement (TTM) | |
|---|---|
| Revenue | CA$29.20m |
| Cost of Revenue | CA$12.71m |
| Gross Profit | CA$16.48m |
| Other Expenses | CA$17.30m |
| Earnings | -CA$823.40k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 56.45% |
| Net Profit Margin | -2.82% |
| Debt/Equity Ratio | 0% |
How did CVAL.F perform over the long term?
See historical performance and comparison